AAAAI: No Increase Seen in Asthma Exacerbations With ICI Use for Melanoma, Renal Cell Carcinoma

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, March 5, 2026 -- For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 27 to March 2 in Philadelphia.

Manan Shah, from the Drexel University College of Medicine in Philadelphia, and colleagues examined asthma exacerbation rates in patients receiving ICIs versus matched controls in a retrospective cohort study utilizing the TriNetX U.S. Collaborative Network. Data were included for 2,329 patients (aged 18 to 80 years) with asthma receiving ICI therapy for melanoma or renal cell carcinoma.

The researchers found that at 24 months, patients receiving pembrolizumab or nivolumab exhibited a modest reduction in exacerbation rates across all asthma subtypes (5.12 versus 7.75 percent). Significant benefit was seen at 24 months in patients with moderate-to-severe persistent asthma (6.82 versus 13.26 percent). No significant differences were seen in exacerbation rates for dual therapy with nivolumab and ipilimumab versus controls.

"Our findings are the first to suggest that moderate-to-severe asthma should not be considered a contraindication to ICI therapy, as these treatments were not associated with worsening asthma exacerbations," Shah said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-06 08:50

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords